http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Joung, Hyou-Arm,Shim, Won-Bo,Chung, Duck-Hwa,Ahn, Jun-Hyoung,Chung, Bong-Hyun,Choi, Ho-Suk,Ha, Sang-Do,Kim, Keun-Sung,Lee, Kyu-Ho,Kim, Cheol-Ho,Kim, Kwang-Yup,Kim, Min-Gon Korean Society for Biotechnology and Bioengineerin 2007 Biotechnology and Bioprocess Engineering Vol.12 No.2
In this study, a specific monoclonal antibody against Listeria monocytogenes was screened using an SPR biosensor. Monoclonal antibodies were bound to protein L, after which the L. monocytogenes cells were subjected to an affinity assay. Protein L was immobilized on a carboxymethyl extran (CM-Dex) surface via an amine coupling method, and utilized repeatedly by regeneration. The monoclonal antibody, 'A18', was selected and employed for the high-sensitivity detection of L. monocytogenes. Under optimized conditions, $10^3 cells/mL$ or 50 cells were detected by the SPR biosensor.
Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
Jun Ho Yi,이경원,이지현,Kwai Han Yoo,Chul Won Jung,Dae Sik Kim,Jeong-Ok Lee,Hyeon Seok Eom,Ja Min Byun,Youngil Koh,Sung Soo Yoon,Jin Seok Kim,Jee Hyun Kong,Ho-Young Yhim,Deok Hwan Yang,Dok Hyun Yoon,Do Hyou 대한혈액학회 2021 Blood Research Vol.56 No.4
Background Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries but is rare in the East Asian countries. Due to its rarity and the lack of feasible novel agents and laboratory prognostic tools, there are limited data on the clinical outcomes of this disease in Asia. To clarify the current treatment status, we performed a multicenter retrospective analysis of patients with CLL in Korea. Methods The medical records of 192 eligible patients between 2008 and 2019 were reviewed for clinical characteristics, treatment courses, and outcomes. The first-line treatment regimens of the patients included in this analysis were as follows: fludarabine/cyclophosphamide/ rituximab (FCR) (N=117, 52.7%), obinutuzumab plus chlorambucil (GC) (N=30, 13.5%), and chlorambucil monotherapy (N=24, 10.8%). Results The median progression-free survival (PFS) was 55.6 months, and the average 2-year PFS rate was 80.3%. PFS was not significantly different between the patients receiving FCR and those receiving GC; however, chlorambucil treatment was associated with significantly inferior PFS (P <0.001). The median overall survival was 136.3 months, and the average 5- and 10-year OS rates were 82.0% and 57.4%, respectively. Conclusion This is one of the largest studies involving Korean patients with CLL. Although the patients had been treated with less favored treatment regimens, the outcomes were not different from those reported in Western studies.